Physitrack
28.7.2021 08:21:56 CEST | ACCESS Newswire | Press release
LONDON, UK / ACCESSWIRE / July 28, 2021 / Physitrack (STO:PTRK)
Second quarter and first half year financial highlights
Second quarter 2020/21 (March 2021 - May 2021)
- Revenue of EUR 1.7m (EUR 0.8m) for the quarter ended 31 May 2021. An increase of EUR 0.9m or 127 per cent compared to the same period last year.
- Proforma[1] revenue growth of 21 per cent for the quarter ended 31 May 2021 compared to the same period last year;
- This growth was achieved in all businesses:
- 34 per cent revenue growth of the existing Physitrack business compared to the same period last year
- 4 per cent revenue growth of the acquired Physiotools and Mobilus (" Physiotools" ) businesses on a proforma basis
- 14 per cent revenue growth of the acquired Rehabplus business on a proforma basis;
- 3 month adjusted EBITDA[2] of EUR 0.6m (EUR 0.5m) increased by 28 per cent compared to the same period last year;
- Strong adjusted EBITDA margins[3] of 36 per cent, decreased from 64 per cent compared to prior year due to lower margins of recently acquired companies;
- Loss before tax of EUR 0.1m (EUR 0.2m profit) for the quarter ended against the comparative period, due to incurring one off IPO and acquisition costs;
- Earnings and diluted earnings per share of EUR -0.01 (EUR 0.02).
First half of financial year 2020/21 (December 2020 - May 2021)
- Revenue of EUR 3.3m (EUR 1.2m) for the 6 months ended 31 May 2021. An increase of EUR 2.1m or 184 per cent compared to the same period last year;
- Proforma1 revenue growth of 37 per cent for the 6 months ended 31 May 2021 compared to the same period last year;
- This growth was achieved in all businesses:
- 65 per cent revenue growth of the existing Physitrack business compared to the same period last year
- 34 per cent revenue growth of the acquired Physiotools and Mobilus (" Physiotools" ) businesses on a proforma basis
- 14 per cent revenue growth of the acquired Rehabplus business on a proforma basis;
- 6 month adjusted EBITDA2 of EUR 1.1m (EUR 0.7m) increased by 61 per cent compared to the same period last year;
- Strong adjusted EBITDA margins3 of 34 per cent, decreased from 60 per cent compared to prior year due to lower margins of recently acquired companies;
- Profit before tax of EUR 0.1m (EUR 0.2m) for the 6 months ended against the comparative period.
- Earnings and diluted earnings per share of EUR 0.01 (EUR 0.02)
Significant events subsequent to the closure of the period
On 18 June 2021 Physitrack PLC successfully completed an initial public offering " Offering" on the Nasdaq First North Premier Growth Market, trading under the ticker "PTRK". We think that First North Premier Growth Market has proven itself as the best place to be for technology-focused entrepreneurial companies in Europe, supporting our ambitious growth plans.
The price per share in the Offering was SEK 40, corresponding to a total value of all the outstanding shares in Physitrack PLC of approximately SEK 624 million upon completion of the Offering. The Offering comprised 4,375,000 newly issued shares, corresponding to a total value of SEK 175 million excluding any over-allotment.
In order to cover any over-allotment in connection with the offering, the Company has issued 655,531 additional ordinary shares net of 731 ordinary shares bought back by the Company's shareholders as part of market stabilisation capabilities This corresponded to 15 per cent of the total number of shares in the Offering " Over-Allotment Option" .
As the Over-Allotment Option was exercised, the Offering constitutes a total of 5,031,250 shares, which corresponds to approximately 31 per cent of the total number of shares in the Company (16,261,497) and total proceeds of approximately SEK 201 million.
The IPO allows the group to continue its acquisition plans in order to expand the business and reinforces the groups position to existing and new customers regarding meeting the various transparency, legal, governance and regulatory requirements a listing brings.
I would like to take this opportunity to thank all my colleagues within the Physitrack group and external parties, who worked tirelessly on the IPO which allowed the company to achieve this significant milestone.
Financial outlook
As outlined within the IPO prospectus, Physitrack's Board of Directors has adopted a set of financial targets linked to the Company's Strategy as set forth below:
- Growth: Physitrack aims to achieve annual organic sales growth exceeding 30 per cent in the medium term, further supplemented by impact from future add-on acquisitions.
- Margin : Physitrack targets an EBITDA margin of 40-45 per cent in the medium term, with potential short term margin extractions due to add-on acquisitions impacting margins negatively.
There are no changes to these financial targets.
Henrik Molin, Co-founder and CEO of Physitrack PLC commented:
"We're delighted to see high levels of customer investments in digital technology in our sector this quarter, and we're confident that digitisation in the healthcare market will continue at a high pace for the foreseeable future. Our solutions and innovations keep being well received by our target markets, and with our new status as a publicly listed company fuelling the enthusiasm of our team and customers, we feel we are extraordinarily well-positioned for future success."
Physitrack PLC's Interim report: December 2020 - May 2021 is available on: https://www.physitrackgroup.com/investors/reports-presentations
Webcast conference
The presentation will be held at 10.00 a.m. CET 28 July 2021 by CEO Henrik Molin and CFO Charlotte Goodwin. The presentation will simultaneously be webcasted, and both webcast conference and the telephone conference offer an opportunity to ask questions. The presentation will be held in English and will be available on https://www.physitrackgroup.com/investors/reports-presentations after the webcast conference.
Link to webcast: here
Dial-in number for telephone conference: here
Enquiries regarding this announcement should be addressed to
Investor contact: Kristian Stålberg, +46 (0) 720 18 05 93, ir@physitrack.com
Media contact: Kristian Stålberg, +46 (0) 720 18 05 93, media@physitrack.com
About Physitrack
Physitrack, founded in 2012, is a global digital healthcare provider, mainly focused on the B2B physiotherapy and musculoskeletal care market. With staff on four continents, customers in 17 time zones, and patients in 187 countries, we are a truly global company.
The company has two business lines:
- Software-as-a-Service (SaaS)-based software platform tailored to physiotherapy and musculoskeletal care, encompassing clinical home exercises, education prescription, outcomes tracking, triaging and Telehealth.
- Virtual care powered by the Physitrack technology platform through in-house physiotherapists based in the United Kingdom.
Physitrack is headquartered in London, United Kingdom, and listed on Nasdaq First North Premier Growth Market (PTRK).
FNCA Sweden AB is appointed Certified Adviser, info@fnca.se , +46 8 528 00 399
[1] Proforma represents the results for the 6 and 3 month period 31 May 2020, had the current structure of the group at 31 May 2021 been in place then. This includes 6 months of trading results up to for Physiotools Oy and Mobilus Digital Rehab AB on the assumption this had been acquired on 30 November 2019 and 3 months of trading results up to for Rehabplus Limited on the assumption this had been acquired on 28 February 2020.
[2] Adjusted EBITDA is defined as earnings before interest, tax, depreciation and amortisation excluding items affecting comparability.
[3] Adjusted EBITDA margins are defined as Adjusted EBITDA as a percentage of revenue
This information is information that Physitrack is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-07-28 08:00 CEST.
Attachments
Physitrack PLC - Interim Report December 2020 - May 2021
SOURCE: Physitrack
View source version on accesswire.com:
https://www.accesswire.com/657388/Physitrack-PLC-Interim-Report-December-2020-May-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
QorusDocs Named LegalTech AI Platform of the Year and Ranked No. 1 Proposal Management Software17.11.2026 15:00:00 CET | Press release
BELLEVUE, WA / ACCESS Newswire / November 17, 2026 / QorusDocs, the pursuit intelligence platform trusted by dozens of Am Law 200 and Global 200 law firms, today announced it has been named LegalTech AI Platform of the Year in the seventh annual LegalTech Breakthrough Awards program and ranked the No. 1 proposal management solution by Info-Tech Research Group's SoftwareReviews, based on verified end-user reviews. The recognitions cap a year of rapid growth in legal for QorusDocs, which forecasts it will double its annual recurring revenue (ARR) from law firms in the next 12 months by adding more high-profile firms to its list of big law customers, which already includes DLA Piper, Baker McKenzie, Herbert Smith Freehills Kramer and Womble Bond Dickinson. Firms are moving AI beyond research and drafting and into business development, where a winning pitch depends on the best representative matters, strong attorney biographies and winning pitch strategies: knowledge general AI tools lack.
Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities17.11.2026 14:00:00 CET | Press release
CORTONA, IT / ACCESS Newswire / November 17, 2026 / Freezz Italia has been awarded a contract by the European Space Agency (ESA), as prime contractor leading a European industrial consortium, for the Consolidation Phase of the IRIS² Low-LEO Pre-Operational and De-Risk Activities, part of the ESA Programme Related to EU Secure Connectivity. The activity will further mature Friisat, Freezz's satellite system architecture conceived specifically for operation in Very Low Earth Orbit (VLEO) and designed for future broadband Direct-to-Device (D2D) connectivity within the 3GPP 5G/6G Non-Terrestrial Network (NTN) framework. Under this ESA contract, Freezz Italia will consolidate the mission and system architecture, adapting Friisat's existing commercial design to meet the requirements of an IRIS²-compatible solution, including future governmental broadband Direct-To-Device secure-connectivity services. The work will address the system and service concepts, architecture and interfaces, security
International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital17.11.2026 11:00:00 CET | Press release
PARIS, FR / ACCESS Newswire / November 17, 2026 / Opti Digital, the leading AdTech company specialising in publisher revenue optimisation, today announced the results of its collaboration with International Business Times UK, an international digital news brand delivering business, markets, technology and current affairs coverage to a global readership. Operating in a fast-moving news environment, International Business Times UK continuously explores opportunities to increase the value of its digital audience while maintaining control over advertising quality and user experience. The publisher identified an opportunity to generate incremental revenue from its existing audience and inventory through a monetisation experience that could be tested progressively and scaled across a broader share of its inventory. "We were looking for ways to generate more value from our existing inventory, and the performance quickly demonstrated the potential of the new experience. It has become a meaning
OBI Pharma Signs Collaboration and License Agreement with Novartis16.11.2026 09:10:00 CET | Press release
TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies. Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes. This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, an
Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q213.11.2026 13:30:00 CET | Press release
MIAMI, FL / ACCESS Newswire / November 13, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) ("Digi Power X" or the "Company"), an AI data center infrastructure operator, today reported its financial and operating results for the third quarter ended September 30, 2026 (all amounts in U.S. dollars, unless otherwise indicated). The Company's quarterly report on Form 10-Q, which includes unaudited consolidated financial statements and management's discussion and analysis ("MD&A") for the quarter ended September 30, 2026, is being filed and made accessible under the Company's continuous disclosure profile on SEDAR+ at www.sedarplus.ca and will also be available on EDGAR at www.sec.gov/edgar. Third Quarter 2026 Highlights All amounts in U.S. dollars (millions) Revenue of $12.25 million, up 85% from the previously completed fiscal quarter and an increase of 50% compared to the quarter ended September 30, 2025; $119.6 million in cash, cash equivalents and digital currencies, $103.0 mill
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
